Moleculin Gets EMA Approval to Expand Phase 3 MIRACLE Trial
May 12, 2025
Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Moleculin Biotech, Inc., a late-stage pharmaceutical